Trial Profile
Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Adverse reactions
- 09 Apr 2024 Status changed from active, no longer recruiting to completed.
- 01 Dec 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 01 Dec 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.